The combination modality of rapid-acting insulin delivered by pump for boluses in combination with subcutaneously injected long-acting insulin once daily may enable all benefits of a pump use among youth with T1D, without deleteriously affecting glycemic control, and while providing protection from DKA. The gene discussed is INS; the disease is type 1 diabetes mellitus.